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Biochemical relapse after radical prostatectomy occurs in approximately 15–40% of patients within 5 years. Postoperative radio-
therapy is the only curative treatment for these patients. After radical prostatectomy, two different strategies can be offered,
adjuvant or salvage radiotherapy. Adjuvant radiotherapy is defined as treatment given directly after surgery in the presence of
risk factors (R1 resection, pT3) before biochemical relapse occurs. It consists of 60–64Gy and was shown to increase biochemical
relapse-free survival in three randomized controlled trials and to increase overall survival after a median followup of 12.7 years in
one of these trials. Salvage radiotherapy, on the other hand, is given upon biochemical relapse and is the preferred option, by many
centers as it does not include patients who might be cured by surgery alone. As described in only retrospective studies the dose
for salvage radiotherapy ranges from 64 to 72Gy and is usually dependent on the absence or presence of macroscopic recurrence.
Randomized trials are currently investigating the role of adjuvant and salvage radiotherapy. Patients with biochemical relapse after
prostatectomy should at the earliest sign of relapse be referred to salvage radiotherapy and should preferably be treated within a
clinical trial.
1. Introduction
Radical prostatectomy (RP) provides excellent cancer control
in patients with localized prostate cancer. However, half of
all patients present with one or more risk factors for recur-
rent disease including higher Gleason Score, extracapsular
extension (TNM tumor classification pT3a), invasion of the
seminal vesicles (pT3b), or positive resection margins (R1).
As a result, the risk of biochemical relapse is approximately
15–40% 5 years after RP [1, 2] and still increasing later
[3] with even higher significance for patients with initially
markedly elevated prostate-specific antigen (PSA) values [4,
5]. In patients with biochemical relapse, median time to
bone metastasis is 8 years [6]. It is more pronounced with
PSA doubling time of <12 months, resulting in a 5-year
metastatic progression-free survival of less than 20% [7].
From several trials, nomograms have been created to assess
the risk of an individual patient for tumor progression [8, 9].
This documents the importance of adequate selection ofmen
after curative intended local treatment of prostate cancer.
Postoperative radiotherapy (RT) can be performed di-
rectly after RP based on risk factors (adjuvant RT), or it is
performed in case of biochemical relapse after RP or in pa-
tients who have persistently detectable PSA levels postop-
eratively (salvage RT). Three randomized controlled trials
investigating the role of adjuvant RT demonstrated improved
biochemical control rates [10–12], whereas metastasis-free
survival and overall survival were improved in only one
trial after 12.7 years of followup [13]. In contrast, to date,
improved biochemical control for salvage RT has been shown
only in retrospective studies.
Despite the lower level of evidence, salvage RT in patients
with biochemical recurrence as compared to adjuvant RT
in all high-risk patients may avoid side effects in at least a
subgroup of patients being already cured by surgery alone
and is therefore the preferred postoperative treatment options
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in many centers. Five years after RP approximately 45–54%
of patients with risk factors remain without evidence of
disease without adjuvant RT. This can be estimated from the
control arms of the three randomized adjuvant RT trials [10–
12]. This paper will provide recommendations regarding the
management of prostate cancer patients, who either have
risk factors for recurrence or already established biochemical
relapse after RP.
2. Materials and Methods
Data for this paper were identified by searches of MEDLINE,
Current Contents, PubMed, and references from relevant
articles using medical subject headings including prostate
cancer, postoperative, radiotherapy, adjuvant, and salvage.
3. Results and Discussion
3.1. Adjuvant Radiotherapy. Three randomized phase III tri-
als have addressed the benefit of adjuvant RT to the prostatic
bed in an immediate postoperative period [10–12]. The
studies are summarized in Tables 1 and 2 as well as below.
Two trials have been initiated in the late eighties and early
nineties of the last century, using old 2 D radiation tech-
niques, and none of these trials provided details of the per-
formed lymph node dissection. Additionally, two out of three
trials allowed the inclusion of patients with postoperatively
elevated PSA values beyond 0.2 ng/mL, which nowadays is
defined as PSA recurrence and therefore represents early
salvage RT as compared to adjuvant RT. Therefore, data and
discussion of these trials have to be interpreted carefully, and
can only be transferred into modern radiation oncology with
caution.
3.2. EORTC 22911 Trial. The European Organisation for the
Research and Treatment of Cancer (EORTC) trial 22911 [10]
included 1005 patients between 1992 and 2001 either having
had pT3a, pT3b, or R1. Patients were randomized to undergo
either RT to the prostatic fossa to a dose of 60Gy at a median
time of 90 days after surgery or observation, respectively.
The primary endpoint was biochemical progression-free
survival (bPFS). Biochemical relapse was defined as a PSA ≥
0.2 ng/mL above postoperative nadir. Initial results were
published after a median followup of 5 years in 2005. Post-
operative RT demonstrated a significant improvement in
bPFS compared to observation (74% versus 52.6%, hazard
ratio (HR) 0.48, 98% confidence interval (CI) 0.37–0.62;
P < 0.0001). There was also a significant reduction in the
cumulative incidence of locoregional recurrence at 5 years
of 5.4% in the RT arm and 15.4% in the observation arm,
respectively (P < 0.0001).
In conclusion, this trial provided strong evidence that
adjuvant RT improved bPFS and local tumour control. Sub-
group analysis after a central pathology review demonstrated
that patients with positive resection margins benefitted most
from adjuvant RT [14]. But this conclusionwas only achieved
by a detailed central pathological review, emphasizing the
disagreement both on the detection of positive margins and
definition of differentiation of the tumor by different pathol-
ogists. Treatment was well tolerated. There was no late grade
4 toxicity reported and the 5-year actuarial incidence of late
grade 3 toxicity was 4.2% in the RT group and 2.6% in the
observation arm (P = 0.07).
3.3. SWOG 8794 Trial. The Southwest Oncology Group
(SWOG) 8794 trial [11] included 425 pT3a, pT3b or R1
patients between 1988 and 1997. Patients received either
adjuvant RT to the prostatic fossa with 60–64Gy or were ob-
served. Postoperative PSA values were available for 376
patients (88%), and 33.8% of patients had PSA values of
0.2 ng/mL and above. Primary trial endpoint was metastasis-
free survival. After a median followup of 12.7 years [13],
adjuvant RT improved the median metastasis-free survival
for 1.8 years (HR 0.71, 95% CI 0.54–0.94; P = 0.016) as well
as the median overall survival for 1.9 years (HR 0.72, 95% CI
0.55–0.96; P = 0.023), respectively. There was no subgroup
in the subset analysis on seminal vesicle infiltration, Gleason
Score, or postoperative PSA value without an improvement
by adjuvant RT. However, patients with a postoperative
PSA > 0.2 ng/mL had a significantly higher risk for metasta-
sis and death (P = 0.03), although the relative improvement
of immediate postoperative irradiation was still the same.
This stresses the value of early adjuvant RT before develop-
ment of PSA recurrence. In contrast, it may also support the
idea that there are risk factors for tumor progression which
cannot be influenced by RT. Unfortunately clinical outcome
of the subgroup of patients in the observational arm who
ultimately received salvage RT for either increasing PSA or
a local recurrence (70 patients, mean PSA value 1.0 ng/mL)
is not provided. This would allow to further characterize
the effect of delayed postoperative RT. Adjuvant RT was well
tolerated; however, urinary incontinence was more common
after RT (6.5%) compared to observation (2.8%) (P =
0.11), and rectal complications including proctitis and rectal
bleeding were only present in the RT arm (3.3% versus 0%,
P = 0.02). In the initial analysis, the incidence of urethral
strictures was significantly higher in the RT arm (17.8%) as
compared to the observation arm (9.5%) (P = 0.02) [11].
In contrast, adjuvant RT did not negatively impact erectile
dysfunction [15].
3.4. ARO 96-02/AUO AP 09/05 Trial. The “Arbeitsgemein-
schaft Radiologische Onkologie (ARO) und Urologische
Onkologie (AUO)” of the German Cancer Society included
388 pT3-4pN0M0 patients into the trial [12]. As an unique
inclusion criteria, all 266 eligible and evaluable patients had
undetectable PSA (<0.1 ng/mL) postoperatively. RT of the
prostatic fossa with 60Gy was compared to observation.
Primary trial endpoint was progression-free survival (PFS)
defined as two consecutive PSA raises above the detection
limit of the test used, local or distant recurrence, or death.
The PFS rates, based on a median followup of 53.7 months,
were significantly improved in the adjuvant RT arm com-
pared to observation (72% versus 54%, HR 0.53, 95% CI
0.37–0.79; P = 0.0015). In an unplanned subgroup anal-
ysis, positive resection margins, absence of seminal vesicle
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Table 1: Characteristics of randomized trials on immediate adjuvant RT.
Trial SWOG 8794 EORTC 22911 ARO 96-02
Year of initiation 1988 1992 1996
Pats.
Randomized
Eligible
Percent
Median age
431
425
98.6%
64.5 years
1005
968
96.3%
65 years
307 from 385 selected
266
87.3%
64 years
Inclusion criteria
cT1-2, post-RP:
Extraprostatic extension and/or
seminal vesicle invasion and/or
positive resection margins
Extraprostatic extension and/or
seminal vesicle invasion and/or
positive resection margins
cT1-3, post-RP:
Extraprostatic extension
and/or seminal vesicle
invasion
pT3 and/or R1, c/p N0 (97% pelvic
LN-dissection) cM0
pT2 R1 or pT3 R0-1, c/p N0 (99%
pN0) cM0
pT3-4 R0-1 pN0 cM0
SWOG PS 0–2
Age not reported
WHO PS 0-1
Age <76 years
WHO PS 0-1
Age <76 years
Postop. PSA
<0.2 ng/mL: 66.2 %
≥0.2 ng/mL: 33.8 %
≤0.2 ng/mL: 88.7%
>0.2 ng/mL: 10.7%
Unknown: 0.6%
<0.1 ng/mL: 100%
Stratification
Positive margins or capsule invasion
versus invasion of seminal vesicles
versus positive margins and capsule
invasion; HT
Institution; capsule invasion; positive
margins; invasion of the seminal
vesicles
Gleason Score; resection
margins; neoadjuvant HT;
tumor stage
Hormonal therapy 8.5% 10.0% 11.5%
Adjuvant RT 30–32 × 2.0Gy 30 × 2.0Gy (in 90.8%) 30 × 2.0 Gy (in 82%)
Time from RP to RT <18 weeks <16 weeks 10–30 weeks
Treatment in
observation arm
RT: 33.2%
RT: 22.5%
HT: 9.1%
Other: 1%
Not reported
Median followup 12.6 years 5 years 4.5 years
Primary endpoint
Metastasis-free survival (bone,
visceral, extrapelvic lymph nodes)
Biochemical progression-free survival Progression-free survival
Definition of bNED
PSA > 0.4 ng/mL for postop.
PSA < 0.4 ng/mL
PSA > 0.2 ng/mL above lowest postop.
PSA
2 increasing PSA values
bNED: biological no evidence of disease; RP: radical prostatectomy; RT: radiotherapy; HT: hormonal therapy; PS: performance status.
invasion, and a preoperative PSA > 10 ng/mL defined pop-
ulations with a nominally significantly proven efficacy of
RT, irrespective of the tumors differentiation. The toxicity
rates were low. No patient experienced grade 4 toxicity. Two
patients in the RT arm developed a urethral stricture.
3.5. Salvage Radiotherapy. Whereas an increase of PSA after
RP of a nonorgan confined cancer can be seen in approxi-
mately 15–40%, a pure local recurrence is predominant with
a slow slope of PSA (>1 year after resection; PSA doubling
time >12 months; PSA increase within 12 months <0.75 ng/
mL), a better differentiated cancer (Gleason Score < 8),
positive margins, and negative pelvic lymph nodes [9, 16].
Outside of clinical trials, a precipitated start of hormonal
therapy can be avoided at least for patients carrying all
favourable risk factors (PSA < 2.0 ng/mL, Gleason Score 4–7,
positive resection margins, PSA doubling time >12 months)
[9, 17]. Thereby, the distinction of local versus systemic tu-
mor progression is not compromised, and additional side ef-
fects can be avoided. So far, the combination of postoperative
RT and hormonal therapy has not been shown to improve
overall survival as compared to postoperative RT alone [9,
17]. Taking this into account, the authors are sceptic on
the value of the recent EORTC trial (NCT00949962) on
adjuvant RT in stage I–III prostate cancer, randomizing 6
months of hormonal therapy in addition to adjuvant RT to
analyze its impact on bPFS. If hormonal therapy is involved,
overall survival seems to be a more appropriate endpoint.
In principle, by irradiation, the PSA can by decreased to
nonmeasurable values in up to 50% of the cases at 5-year
followup [9, 18]. The observation from large retrospective
trials as well as from the randomized trials of SWOG and
EORTC suggests the need to start salvage RT at the earliest
sign of biochemical failure, with PSA value being between 0.2
and 0.5 ng/mL [18–20]. The development of a measurable
local recurrence should be avoided, because in these patients
outcome after salvage RT seems to be worse [18, 21, 22].
Unfortunately, there are only retrospective studies available
addressing the benefit of salvage RT (Table 3). Trock et al.
analyzed 635 patients undergoing RP in the years of 1982 to
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Table 2: Results of randomized trials on immediate adjuvant RT.
Trial SWOG 8794 EORTC 22911 ARO 96-02
Overall survival
HR: 0.72
(95% CI 0.55–0.96),
P = 0.023
HR: 1.09
(98% CI 0.67–1.79),
P = 0.68
Not reported
bNED
HR: 0.43
(95% CI 0.31–0.58),
P < 0.001
HR: 0.48
(98% CI 0.37–0.62),
P < 0.0001
HR: 0.53
(95% CI 0.37–0.79),
P = 0.0015
Metastasis-free survival
HR: 0.71
(95% CI 0.54–0.94),
P = 0.016
Not reported
98% versus 95.1 %
(n.s.)
Clinical progression-free
survival
HR: 0.62
(95% CI 0.46–0.82),
P = 0.001
HR: 0.61
(98% CI 0.43–0.87),
P = 0.0009
Not reported
Time to initiation of
hormonal therapy
HR: 0.45
(95% CI 0.29–0.68),
P < 0.001
Not reported Not reported
Overall toxicity
23.8% versus 11.9%,
P = 0.002
4.2% versus 2.6%
(Grade 3; P = 0.07)
21.9% versus 3.7%,
P < 0.0001
Rectal toxicity
3.3% versus 0%,
P = 0.02 Not reported 1.4% versus 0%
Urinary stricture
17.8% versus 9.5%,
P = 0.02 Not reported Not reported
Total urinary incontinence
6.5% versus 2.8%,
P = 0.11 Not reported Not reported
HR: hazard ratio; CI: confidence interval; n.s.: not significant.
2004 who experienced biochemical and/or local recurrence
and received either no salvage treatment (n = 397), salvage
RT alone (n = 160), or salvage RT combined with hormonal
therapy (n = 78), respectively [17]. Median dose was
66.5Gy for patients with salvage RT and 67.2Gy for patients
receiving salvage RT and hormonal therapy. After a median
followup of 6 years, salvage RT alone was associated with a
3-fold increase in prostate-cancer-specific survival compared
to those with no salvage treatment (HR 0.32, 95% CI 0.19–
0.54; P < 0.001). Use of hormonal therapy was not associated
with additional increase in prostate-cancer-specific survival.
The increase in prostate cancer-specific survival associated
with salvage RT was most marked in men with a PSA dou-
bling time of less than 6 months and in patients with a Glea-
son Score of 8–10. This is an important finding as it suggests
that patients with prostate cancer and adverse risk factors
profit most from salvage RT. It is in contrast to other data,
emphasizing the higher probability of a local tumor growth
with long PSA doubling time and better differentiated cancer,
and therefore a better and longer lasting effect on biochemi-
cal control [23, 24]. Therefore, until results from randomized
trials become available, it seems not justifiable to refuse the
admittance of salvage RT to any subgroup of patients.
A large multi-institutional retrospective study by Steph-
enson et al. analyzed 1540 patients who underwent salvage
RT for biochemical relapse between 1987 and 2005 [9]. The
primary study endpoint was defined as disease progression
after salvage RT with PSA value ≥0.2 ng/mL above post-RT
nadir, initiation of systemic therapy, or clinical progression.
A total of 214 patients (14%) received neoadjuvant and/or
concurrent hormonal therapy for a median duration of 4.1
months. Median RT dose was 64.8Gy. The median followup
was 53 months. Overall, the 6-year progression-free prob-
ability (PFP) after salvage RT was 32%. However, when
analyzed according to PSA levels at initiation of treatment, an
estimated 48% who received salvage RT without hormonal
therapy at a PSA level ≤0.50 ng/mL were disease-free at 6
years compared to 40%, 28%, and 18% of those treated
at PSA levels of 0.51–1.00, 1.01–1.50, and greater than
1.50 ng/mL, respectively. These results suggested the need for
salvage RT at the earliest sign of biochemical relapse after
RP. The 4-year PFP estimates after salvage RT alone were
still improved in patients with high-risk features such as
PSA ≥ 2 ng/mL before salvage RT, Gleason Score of 8–10,
and PSA doubling time of≤10months [9, 24]. However, data
from randomized controlled trials are lacking.
Overall, most clinical data support that a high percentage
of patients with rising PSA after RP have a local recurrence.
RT to the prostatic bed alone allows long lasting tumor
control, avoiding the toxicity of pelvic lymphatic irradiation
and additional hormonal therapy as well. It seems reasonable
to follow the guidelines on target volume definition from
the EORTC Radiation Oncology Group, to reach an optimal
compromise on both target volume coverage and sparing of
critical organs and structures at risk. For the authors, it is a
prerequisite to use such guidelines not only for participating
in clinical trials on prostate cancer, but when highly sophis-
ticated modern RT techniques with steep dose decrease close
Prostate Cancer 5
Table 3: Characteristics and results of retrospective reports on salvage RT.
First author Year No. Pats.
Median
pre-RT-PSA
(ng/mL)
HT (%)
Med.
RT-dose
(Gy)
RT technique
Followup
(months)
bNED (%)
Anscher et al. [25] 2000 89 1.4 9 66.0 2 D/3 D 48 50 (4 y.)
Bernard et al. [26] 2010 364 0.6 0 64.8 2 D/3 D 72 50 (5 y.)
De Meerleer et al. [27] 2008 87 0.7 56 75.0 IMRT 30 67 (5 y.)
Do et al. [28] 2002 73 2.8 9 64.8 2 D 42 45 (10 y.)
King and Spiotto [29] 2008 84 0.45 57 70.0 2 D/3 D/IMRT >60 58 (5 y.)
Loeb et al. [30] 2008 107 ∼0.7 0 63.0 IMRT 53 55 (7 y.)
MacDonald et al. [22] 2004 102 1.1 0 65.8 n.r. 50 38 (5 y.)
Neuhof et al. [20] 2007 171 1.1 29 60–66 3 D 39 35 (5 y.)
Pazona et al. [31] 2005 223 0.8 4.5 63 3 D 56 40 (5 y.)
Pisansky et al. [32] 2000 166 0.9 4 64.0 2 D/3 D 52 46 (5 y.)
Stephenson et al. [24] 2004 501 0.7 17 64.8 2 D/3 D/IMRT 45 45 (4 y.)
Stephenson et al. [9] 2007 1540 1.1 14 64.8 2 D/3 D/IMRT 53 32 (6 y.)
Trock et al. [17] 2008 160 0.7 0 66.5 2 D/3 D 72 89 (10 y. OS)
Van Der Poel et al. [33] 2008 41 2.15 7 60–70 n.r. 73 44 (10 y.)
Wiegel et al. [19] 2009 162 0.33 0 66.0 3 D 41 54 (3.5 y.)
RT: radiotherapy; HT: hormonal therapy;Med. RT dose: median total dose of radiation therapy; bNED: biochemical no evidence of disease; n.r.: not reported;
2 D: 2-dimensional treatment planning; 3D: 3-dimensional treatment planning; IMRT: intensity-modulated radiation therapy; OS: overall survival.
to the margins of the planning target volume are being used,
in order to prevent out volume or marginal local recurrences
[34].
3.6. Effect of Dose Escalation. In accordance with the well-
described dose-escalation trials for primary RT of localized
prostate cancer [35], it has recently been proposed that dose
intensification either for salvage RT [29, 36] or adjuvant RT
[37] would bemore effective in terms of cancer control. From
very recent retrospective reports, it became obvious that total
doses of more than 66Gy can be used safely when modern
techniques are available [26, 27, 29, 36]. Nevertheless,
intensity-modulated RT to the prostate bed-up to 75Gy was
associated with 30% late grade 2 genitourinary toxicity [27].
Also, it has been suggested that each Gy increase in total
dose may improve the biochemical tumor control by more
than 3%, having doses between 64 and 70Gy still in the
steep part of the dose-response curve [29]. Therefore, a total
dose towards 70Gy might be considered in salvage situation,
when the risk of severe toxicity can be minimized by using
modern radiation techniques. In the absence of results from
randomized trials, the potentially improved local tumor
control by higher RT dose should be carefully weighted out
against possibly increased toxicity. In principle, toxicity of
salvage RT with total doses of about 70Gy is low with less
than 3% of late grade 3 proctitis or genitourinary side effects,
respectively. [19, 27, 33, 38].
However, the dose-dependent effect has never been pro-
spectively assessed both in the adjuvant or salvage setting.
The Swiss Group for Clinical Cancer Research (SAKK) is
conducting a randomized controlled international trial com-
paring salvage RT with 64Gy and 70Gy without hormonal
therapy in patients with prostate cancer and biochemical
relapse after RP (SAKK 09/10, NCT01272050). The trial will
include men ≤75 years with pT2-3 N0 R0-1, with a PSA of
at least ≥0.1 ng/mL and rising but ≤2 ng/mL. Patients with
evidence of macroscopic recurrence or metastatic disease
are excluded. It is estimated to enroll 350 patients, and the
trial is currently recruiting patients. The primary endpoint
is freedom from biochemical progression including a PSA of
≥0.4 ng/mL and rising and/or clinical failure. The trial will
contain quality of life analysis, quality assurance of RT, and a
central pathology review.
3.7. Adjuvant versus Salvage Radiotherapy. The advantages of
immediate adjuvant RT are obvious from three randomised
trials, achieving a biochemical control at 5 years ofmore than
20% higher than from salvage RT [10–12, 39]. Nevertheless,
it has to be taken into account that in two out of three trials
on adjuvant RT, more than 25% of the included patients
had a PSA of more than 0.2 ng/mL at the initiation of RT
which corresponds to a “salvage-like” situation [10, 11].
Importantly, the alternative concept of salvage RT avoids
treatment of patients without tumor progression after RP
despite having risk factors such as R1 or pT3b. The toxicity
and morbidity of urethral stenosis and incontinence can be
abstained by starting RT years after full recovery from RP.
There have been multiple retrospective clinical trials
comparing the influence of either immediate adjuvant or
salvage RT on local control and/or biochemical control [40].
Consistent improvements in both endpoints have been ob-
served. The biochemical control at 5 years was approximately
69–89% for adjuvant and only 39–68% for salvage RT. Local
control rates were higher than 95% for adjuvant and 79–93%
for salvage treatment. Of course, this can be explained, at
least in part, by a selection bias in favour of adjuvant RT, since
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it is known that roughly half of the patients who underwent
adjuvant RT would not experience a PSA recurrence even
without RT;moreover, the PSA values in the salvage situation
are higher, indicating a higher tumor load demanding higher
radiation doses.
Three randomized clinical trials are currently comparing
the timing of RT to answer if immediate adjuvant policy will
be any more effective than a salvage policy. The RADICALS
(radiotherapy and androgen deprivation in combination
after local surgery) trial (NCT00541047) conducted by the
Medical Research Council (UK) and the National Cancer
Institute of Canada Clinical trials Group aims to recruit
4000 patients; primary endpoint is 10-year prostate-cancer-
specific survival. The trial has two randomizations steps, one
regarding the time of RT with a dose of 66Gy to the prostatic
fossa and one regarding use of combined six months hor-
monal therapy with postoperative RT.
The French Groupe d’ E´tude des Tumeurs Uro-Ge´nitales
(GETUG) has activated the GETUG-17 trial (NCT00667069)
comparing adjuvant versus salvage RT combined with 6
months of hormonal therapy. The estimated enrolment is
718 patients, and the primary endpoint is event-free survival
(including biochemical progression) at 5 years.
Finally, the RAVES (radiotherapy adjuvant versus early
salvage) trial (NCT00860652) has been activated by the Tas-
man Radiation Oncology Group (TROG) comparing adju-
vant versus salvage RT (64Gy) without hormonal treatment.
The estimated enrollment is 470 patients, and the primary
endpoint is biochemical failure.
Until results of these trials become available, the optimal
timing and dose of postoperative RT and the value of addi-
tional hormonal therapy remain unknown.
Nevertheless, based on evaluation of risk factors for bio-
chemical or clinical failures coming from previous retro-
spective analysis and three recent randomized trials, most
patients with R1, pT3 disease may be offered immediate
postoperative RT [10, 12, 13]. Besides, patients with preop-
erative PSA values of more than 10 ng/mL and a preoperative
PSA velocity of >2 ng/mL per year may also benefit from
immediate adjuvant RT in terms of improved biochemical
control, but this has not been proven by randomized trials
[3, 4, 12, 14, 41]. For all the other patients carrying less
pronounced risk factors for tumor recurrence, it seems more
reasonable to balance the superior initial quality of life and
the lower risk of clinical or PSA recurrence in favour of
salvage RT. A score algorithm or nomograms may help in
decision making [6, 9, 42] using risk factors for recurrence as
seminal vesicle infiltration, Gleason Score, and pre-RT PSA-
value.
On the other hand, the natural course and life expectancy
of men besides prostate cancer have to be considered, with
its enormous global inequality [43]. With a realistic life
expectancy of less than 5 years, further treatment should not
be offered in the adjuvant situation, and even with a life
expectancy of up to 8 years, salvage RT seems to be appro-
priate.
Thereby, it should be remembered that it needs about 8
years from biochemical recurrence to the development of a
clinically measurable progression [6].
4. Conclusions
The use of adjuvant RT after RP in patients with adverse risk
factors has demonstrated improved biochemical control and
overall survival. However, there is a relevant risk of overtreat-
ment as patients might be included who are cured by surgery
alone. We recommend to offer adjuvant RT to all patients
with R1 resection and pT3 disease and to also consider
preoperative PSA values of more than 10 ng/mL and a
preoperative PSA velocity of >2 ng/mL per year as additional
risk factors for tumor recurrence.
Alternatively, patients can be treated with salvage RT in
the event of biochemical relapse, especially when they are
carrying less dominant risk factors for tumor recurrence. It
is recommended that such salvage RT should be performed
as early as possible, preferably with PSA values below 0.5 ng/
mL, and although it was shown to be most effective in pa-
tients with adverse risk factors, it should not be withhold
from any definite subgroup of patients with biochemical
recurrent disease. The optimal dose and timing of postop-
erative RT is subject of national and international phase III
trials. Outside of clinical trials, 60–64Gy should be used
in the immediate postoperative setting and 64–72Gy in the
salvage setting, dependent on the absence or presence of
macroscopic recurrence. Patients with biochemical relapse
after RP should be treated within clinical trials to answer
open questions on dose and timing as soon as possible.
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